Investigational gefurulimab met its primary efficacy endpoint in adults with anti-acetylcholine receptor (AChR) ...

Topline phase 3 results show that the novel nanobody gefurulimab is safe and effective for AChR-antibody-positive myasthenia ...

While AstraZeneca's gefurulimab offered significant improvements to MG-ADL scores, it was bested by a variety of ...

【阿斯利康】周四宣布，其在研抑制剂Gefurulimab的III期临床试验在重症肌无力患者的日常生活活动方面达到了主要终点。 这家总部位于英国剑桥的制药公司表示，与安慰剂相比，Gefurulimab在第26周时显示出改善，早在第一周就观察到具有临床意义的改善，并持续到第26周。全身型重症肌无力是一种罕见的自身免疫性疾病，其特征是肌肉功能丧失和严重的肌肉无力。 阿斯利康罕见病部门Alexion的研发 ...

这家总部位于英国剑桥的制药公司表示，Gefurulimab在第26周时显示出比安慰剂的改善，早在第一周就观察到具有临床意义的改善，并持续到第26周。全身型重症肌无力是一种罕见的自身免疫性疾病，其特征是肌肉功能丧失和严重的肌肉无力。

AZ is already a major presence in gMG treatment with its current antibody-based anti-C5 drugs – Soliris (eculizumab) and ...

PREVAIL phase III trial of gefurulimab meets its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement from baseline in MG-ADL ...

Results from the global PREVAIL Phase 3 trial showed that gefurulimab met its primary endpoint, demonstrating a statistically significant and ...

(Alliance News) - AstraZeneca PLC on Thursday said phase 3 data regarding its investigational inhibitor gefurulimab met its primary endpoint in myasthenia gravis activities of daily living.

AZ has already made it clear its focus is on investing in the US market – which accounts for 30% of its sales – and started ...

Q3 2025 Earnings Call November 6, 2025 8:00 AM ESTCompany ParticipantsAndrew Barnett - Head of Investor RelationsPascal Soriot - ...

Across our pipeline we have announced an unprecedented 16 positive Phase III trials this year, with four since our previous results including high-impact readouts for baxdrostat in hypertension and ...